EUFLEXXA—Proven results to help keep you moving forward2,3
What results did EUFLEXXA have in patients with OA of the knee?
Study design: The effectiveness and safety of EUFLEXXA was shown to be comparable to another HA product in a head-to-head clinical trial. The study was conducted in 321 patients with OA knee pain over a 12-week period.2,3*
In a 12-week clinical trial, patients experienced2,3:
Powerful pain relief
Pain relief began as early as 1-week after the first injection and continued to improve after each one
Week After
1st INJECTION
(n=160)
2nd INJECTION
(n=159)
3rd INJECTION
(n=159)
Mean change (%) from baseline WOMAC pain score.
Weeks After
Synvisc
3rd INJECTION
(n=158)
EUFLEXXA
3rd INJECTION
(n=157)
Both treatments showed meaningful improvements from baseline (P<0.0001).2,3
Pain-free is defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20mm).
After 3 injections, patients had significantly less pain associated with 5 basic functions3†
Climbing Stairs
Walking
Standing
Sitting
Resting During Night
Less pain medication needed3‡
Patients treated with EUFLEXXA needed less pain medication compared to patients treated with another HA injection
Higher satisfaction3
Patients treated with EUFLEXXA were satisfied with the pain relief they experienced
Adverse Events
Most common adverse events in the clinical trial include joint pain (11/160), increase in blood pressure (3/160), joint swelling (3/160), feeling of sickness (3/160), tingling (2/160), back pain (1/160), nausea (1/160), skin irritation (1/160), tenderness in study knee (1/160).2,3
Please see additional Important Safety Information.
*Based on % reduction in Western Ontario and McMaster Universities Osteoarthritis Index pain score from baseline in a pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158). Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = 101/160.
†Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.
‡Acetaminophen was the only additional medication provided.
Ready to get started?
Ask your doctor:
“Is EUFLEXXA, the HA injection that works in 2 ways, right for me?”
Find a Doctor- Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
- EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
- Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.